R&D and Innovation


3D1002 is an E-type prostanoid receptor 4 (EP4) receptor antagonist. IND approval was obtained from the NMPA in July 2018. As of the date of this report, we have completed the manufacture of clinical batch Drug Product (DP), and 3D1002 is a potentially effective target candidate for cancer pain and is currently in the advanced stage of clinical trials.


Function of EP4 in anti-inflammatory and analgesic effects

The receptors of the critical PGE2 include 4 sub-types EP1/2/3/4. EP4 (also named PTGER4), a G-protein coupled receptor, is the critical receptor of PGE2, and its activation will increase the inflammatory reaction in cells. Recent studies also showed a potential function of EP4 in tumor generation and growth.